Exelixis, Inc. — 2017 Form 10-K summary
Period note: The request metadata says “2016 Q4,” but the supplied filing is Exelixis’s 2017 Form 10-K, covering its 52-week fiscal year ended December 29, 2017. The filing presents annual amounts using December 31 labels for convenience. It also includes unaudited fourth-quarter results.
Business context and reporting period
Exelixis is an oncology biotechnology company. Its main commercial driver was CABOMETYX (cabozantinib), approved in 2017 for both previously treated and previously untreated advanced renal cell carcinoma (RCC). COMETRIQ is approved for medullary thyroid cancer (MTC); COTELLIC (cobimetinib) is marketed with Genentech for advanced melanoma. Exelixis reports one business segment.
Key financial metrics
| Metric | FY 2017 | FY 2016 |
|---|---|---|
| Total revenue | $452.5 million | $191.5 million |
| Net product revenue | $349.0 million | $135.4 million |
| Collaboration revenue | $103.5 million | $56.1 million |
| Operating income (loss) | $165.9 million | ($28.1 million) |
| Net income (loss) | $154.2 million | ($70.2 million) |
| Diluted earnings (loss) per share | $0.49 | ($0.28) |
| Operating cash flow | $165.6 million | $210.4 million |
| Cash and investments at year-end | $457.2 million | $479.6 million |
| Debt at year-end | None | $189.1 million |
- Revenue increased 136% year over year. CABOMETYX net product revenue was $324.0 million, up from $93.5 million; COMETRIQ revenue fell to $25.0 million from $41.9 million.
- Gross margin was 96%, versus 95% in 2016. Approximate operating margin was 36.7% and net margin 34.1%.
- R&D expense rose 17% to $112.2 million; selling, general and administrative expense rose 37% to $159.4 million.
- Operating cash flow declined despite the return to profitability, in part because 2016 included Ipsen’s $200 million upfront payment. 2017 investing cash flow was $35.8 million provided, including investment maturities and purchases; property and equipment purchases were $21.1 million.
- At year-end, current assets were $484.9 million and current liabilities $115.2 million; working capital was $369.7 million. Management said cash resources and expected product and collaboration revenue should fund operations for at least 12 months after filing.
Material changes versus the prior comparable period
- Commercial growth in CABOMETYX drove the increase in product revenue; the FDA expanded its RCC indication in December 2017 to include previously untreated patients.
- Collaboration revenue increased, reflecting milestones, license revenue, royalties, product supply and development reimbursements. The filing records $45 million of Ipsen milestones related to the EU first-line RCC filing and $12.5 million of BMS ROR collaboration milestones.
- Exelixis repaid its $80 million Silicon Valley Bank term loan and retired the Deerfield notes for $123.8 million in 2017. The early retirement of the Deerfield notes generated a $6.2 million extinguishment loss but reduced future interest expense.
- Net income was also affected by lower interest expense, higher operating expenses, and collaboration-related revenue. 2016 results included a $23.1 million Genentech cost recovery in the fourth quarter, making year-over-year quarterly comparisons less straightforward.
- FY 2017 CABOMETYX revenue is reported as $324.0 million in the detailed financial tables; the filing’s business overview separately cites $323.1 million. Investors should confirm the intended measure and reconciliation.
Fourth-quarter results and outlook
Unaudited fourth-quarter 2017 revenue was $120.1 million, operating income $37.4 million and net income $38.5 million. In fourth-quarter 2016, revenue was $77.6 million and net income $35.1 million, including the Genentech cost recovery noted above.
Management’s 2018 priorities were to expand CABOMETYX sales in first-line RCC, prepare for a potential HCC launch, continue cabozantinib development, advance internal discovery and pursue licensing or acquisition opportunities. The filing provides no numerical 2018 revenue or earnings guidance. Management expected R&D and SG&A expenses to increase in 2018.
- CELESTIAL, a Phase 3 trial in previously treated advanced HCC, met its primary overall-survival endpoint. Management planned an FDA supplemental application in Q1 2018 and reported Ipsen intended an EU filing in the first half of 2018.
- A Phase 3 trial of cabozantinib plus nivolumab in first-line advanced RCC and multiple other combination studies were underway. These programs offer potential but carry clinical, regulatory and funding uncertainty.
- Genentech continued Phase 3 cobimetinib studies; IMblaze370 results were expected in the first half of 2018. Exelixis depends on Genentech’s development and commercialization decisions for COTELLIC.
- Adoption of the new revenue standard in 2018 was expected to materially change the timing of collaboration revenue recognition and reduce opening accumulated deficit by approximately $260 million. The filing described this as an accounting transition, not a change to product-sales revenue.
Risks, contingencies and unusual items
- Future performance depends heavily on CABOMETYX sales, market acceptance, reimbursement and continued regulatory progress. Competition includes established therapies and emerging immunotherapy combinations; the FDA’s 2018 draft cabozantinib bioequivalence guidance could signal generic-development interest, though the filing says this is uncertain.
- Product supply depends on third-party manufacturers and logistics providers. Exelixis also relies on Ipsen and Takeda for international cabozantinib commercialization and on Genentech for COTELLIC.
- Clinical development may fail or be delayed, and adverse events, trial results or regulatory decisions could affect approvals and sales. The filing notes treatment-related Grade 5 adverse events in CELESTIAL.
- Drug pricing pressure, changing healthcare policy, payer coverage and discount obligations may reduce revenue or margins. Discounts and allowances as a percentage of gross product revenue were expected to increase in 2018.
- Exelixis recorded a $184.8 million reduction in deferred tax assets following 2017 U.S. tax reform, offset by a reduction in its valuation allowance; it maintained a full valuation allowance on remaining deferred tax assets. It reported $79.3 million in unrecognized tax benefits.
- The company planned a headquarters move to Alameda in 2018 and expected related costs and possible operational or employee disruption. It disclosed no material legal proceedings and no material off-balance-sheet arrangements.
- The financial statements received an unqualified audit opinion; management and the auditor reported effective internal control over financial reporting.
Important facts for investors to verify
- Reconcile the $324.0 million CABOMETYX net revenue in the financial tables with the $323.1 million figure in the business overview.
- Assess how much 2017 earnings depended on collaboration milestones and accounting recognition, versus recurring product sales and cash generation.
- Track launch performance, discount and rebate trends, payer access, and competitive positioning for CABOMETYX in both RCC settings.
- Monitor HCC regulatory filings and trial outcomes, including safety findings, as well as progress and cost-sharing for cabozantinib combination trials.
- Review the 2018 revenue-standard transition and its effect on reported collaboration revenue, accumulated deficit and comparability with prior periods.
- Confirm cash available for operations, investment liquidity, and execution of the Alameda facility move and planned spending increases.